Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933606 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of BNC210 in PTSD
A Phase 2 study, sponsored by Bionomics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT02933606: Completed Phase 2 study, sponsored by Bionomics Limited.
NCT02933606 is a Phase 2 study that has completed, run by Bionomics Limited. The registered enrollment target is 193 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933606, a Phase 2 study, has completed, sponsored by Bionomics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.
Primary Outcome
Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
Interventions
- DRUG Placebo
- DRUG BNC210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2018-07-25 |
| Phase | Phase 2 |
What the finished NCT02933606 record still lists
NCT02933606 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02933606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02933606 about?
NCT02933606 is a clinical study titled "Phase II Study of BNC210 in PTSD". This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects...
What is the current status of trial NCT02933606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2016-06-30. Estimated completion is 2018-07-25.
What interventions are being tested in trial NCT02933606?
The interventions under investigation include: Placebo (DRUG), BNC210 (DRUG).
Who is sponsoring clinical trial NCT02933606?
This trial is sponsored by Bionomics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02933606's enrollment target sits among peer trials
193 352nd of 2000 higher than 1,649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI